Israel Angels Law: Tax Benefits for Foreign Investors in Israeli Startups

Israel has one of the highest densities of technology startups per capita in the world, and foreign angel investors have been putting money into Israeli early-stage companies for decades. What many foreign investors do not know is that the Israeli government runs a dedicated tax incentive program specifically designed to attract those investments — and the current version of that program expires on December 31, 2026.

The Angels Law tax credit is not widely publicized outside specialist Israeli tax circles, partly because it has gone through several iterations and a gap period. The original Angels Law expired at the end of the 2019 tax year. After years of lobbying by the Israeli high-tech sector, the Knesset passed the Law for the Encouragement of Knowledge-Intensive Industries 5783-2023 as a Temporary Order, restarting the credit retroactively from July 2023 through December 2026. That gives eligible investors who act before year-end a meaningful tax benefit that the prior four-year gap denied.

The Israel Innovation Authority certification process is the step most investors miss. There is still time to structure a qualifying investment correctly before year-end, but the logistics take longer than most foreign investors expect.

1. What the Angels Law Is (and Is Not)

The formal name of the current law is the Law for the Encouragement of Knowledge-Intensive Industries 5783-2023, which operates as an amendment to the Income Tax Ordinance. In the Israeli market it is universally called the "Angels Law" (Chok HaMalakhim). The tax mechanism is set out in Sections 20A through 20B of the Income Tax Ordinance.

The law creates a tax credit — not a deduction. A deduction reduces taxable income; a credit reduces the tax itself, shekel for shekel. That distinction matters enormously at high Israeli tax brackets. An investor in the 50% marginal bracket who invests NIS 1 million in a qualifying startup receives a credit of NIS 250,000 against their Israeli tax bill directly — not a reduction in the amount of income they report.

The credit rate equals the Israeli capital gains tax rate applicable to the investor. For most individual investors that is 25%. For corporate investors (a company investing in a startup) the applicable rate depends on the corporate tax rules — typically 23%, though the specific calculation for a corporate investor requires separate analysis. This guide focuses on individual investors, who form the majority of angel investors using this program.

One important framing: the credit is technically a deferral, not a permanent exemption. When the investor eventually sells the shares, Israeli capital gains tax applies to the full gain — but the original investment amount that was credited is treated as if it had been deducted from cost, meaning the taxable gain on exit is calculated from zero cost basis for the credited amount. In practice this means an investor who holds for three or more years and then exits pays normal capital gains tax on the appreciation, with the initial credit having provided a zero-interest government loan during the holding period.

2. Foreign Investors: Are You Eligible?

The short answer is yes. The law explicitly covers both Israeli residents and foreign investors. There is no citizenship or residency requirement for the investor.

However, the mechanism works differently depending on whether you pay Israeli taxes. An Israeli resident investor applies the credit against Israeli income tax or capital gains tax owed in the year of investment. A foreign investor who has no other Israeli tax liability in that year cannot apply the credit immediately — it carries forward and applies against Israeli capital gains tax when the shares are eventually sold.

This carryforward structure still provides real value for a foreign investor because it reduces the exit tax when they eventually sell their Israeli shares. Most foreign investors in Israeli companies will have some Israeli-source capital gains on exit, particularly if the company grows and they sell to an Israeli acquirer or in a transaction with Israeli nexus. The credit then reduces what would otherwise be a 25% Israeli capital gains tax obligation on their share of the exit proceeds.

There is one significant limitation for foreign investors: the investor cannot be an "interested party" in the R&D company at the time of investment. Under Section 20A(d) of the Income Tax Ordinance, an interested party means any person holding 25% or more of any class of shares, or with equivalent rights to appoint directors or receive profits. A lead investor who already holds 30% of the company cannot make a follow-on investment and claim the Angels Law credit on that additional amount. A first-time investor taking a minority stake has no such restriction.

3. What Qualifies as an R&D Company?

Not every Israeli startup qualifies for the Angels Law credit. The investee company must meet the definition of an "R&D company" (chevrat machkar ufituach) under the Temporary Order. The qualification criteria exist because the credit is designed to support early-stage, pre-revenue technology development, not established businesses or companies that have already commercialized their technology.

An R&D company must satisfy all of the following conditions at the time of investment:

• At least 70% of the company's total expenditure in each of the two preceding tax years must consist of approved research and development expenses. Companies operating for less than two years are assessed from inception.
• The company must not yet have significant commercial revenues. The IIA treats a company as pre-commercial when its cumulative revenues have not yet exceeded a threshold consistent with an early-stage entity. Most qualifying companies are at Seed or Series A stage with minimal or no product revenues.
• The company must be a private company limited by shares registered with the Israeli Companies Registrar under the Companies Law 5759-1999.
• The company must hold a qualifying certificate from the Israel Innovation Authority (IIA, formerly the Office of the Chief Scientist, located at HaArba'a Street 30, Tel Aviv). This certificate must be held by the time the company's annual tax return for the investment year is filed.

The IIA qualification process is the most commonly missed step. Founders of early-stage companies often do not know about the Angels Law, or they know about it but assume the certificate is the investor's problem. In fact, the certificate obligation sits with the company. A foreign investor should make the IIA certificate a closing condition in the investment documentation — meaning the investment only closes once the company has confirmed with the IIA that it qualifies or has a pending application.

4. How the tax credit mechanism actually works

The credit is calculated as: investment amount × 25% (for individual investors subject to Israeli capital gains tax at the standard rate). The credit applies to the tax year in which the cash investment is made and received by the company.

For an Israeli tax resident, the credit applies directly against Israeli taxes owed that year. If the investor has no Israeli income that year, the credit carries forward with no expiry until the investor has Israeli tax to apply it against — typically on the exit from the investment itself.

For a foreign investor with no Israeli income in the investment year, the credit sits dormant and applies on exit. When the investor sells their shares in the Israeli company, they will owe Israeli capital gains tax on the gain. The deferred credit reduces that exit tax liability, effectively subsidizing the investment cost.

The credit is not refundable. This means an investor who has no Israeli tax in any year and never exits the investment cannot receive a cash refund from the Israel Tax Authority. The value of the credit depends entirely on whether and when the investor generates Israeli-source income or capital gains to apply it against. For investors going into companies they expect to grow and be acquired, this is usually not an issue. For investors with no expectation of Israeli-source income, the credit may be less valuable than it appears on paper.

The Israel Tax Authority (ITA, Rashut HaMisim) administers the credit. Foreign investors who claim Angels Law credits on exit from an Israeli investment do so through their Israeli capital gains tax filing. The ITA's Non-Residents Unit at the Tel Aviv District handles most foreign investor filings.

5. Investment limits and the mandatory holding period

Two hard limits determine the maximum value an investor can extract from the Angels Law credit.

The first limit is the per-company ceiling. The maximum qualifying investment in any single R&D company is NIS 4 million per investor. Investments above NIS 4 million in the same company do not generate additional credit. An investor who puts NIS 6 million into one startup receives a credit on only NIS 4 million of that amount (NIS 1 million at 25%), not the full NIS 6 million.

There is also an aggregate annual ceiling per investor across all qualifying investments, though the exact cap is subject to ITA administrative interpretation and varies by the investor's tax classification. Investors planning multiple qualifying investments in the same tax year should confirm the applicable ceiling with an Israeli tax advisor before closing.

The third limit is the mandatory holding period. The investor must hold the shares for at least three years from the date of investment. Selling, transferring, or pledging the shares before three years triggers full reversal of the credit plus interest under Section 190 of the Income Tax Ordinance (currently approximately 4% annual interest plus CPI linkage). In a startup context this means tag-along sales, drag-along exercises, and secondary share sales all carry clawback risk if they occur within the holding window.

One exception: if the company goes into receivership or liquidation before three years, the ITA generally does not claw back the credit, on the basis that the investor suffered a total loss with no voluntary sale. This position should be confirmed with the ITA in any specific situation.

6. How to claim the credit: the filing process

The credit is claimed through the Israeli tax filing system, not through the IIA. The sequence for a foreign investor works as follows:

1. Before investing, confirm the company has applied for or holds an IIA qualifying certificate. Make this a closing condition in the investment agreement or term sheet.
2. Wire the investment in cash to the company's Israeli bank account within the 2023 to 2026 Temporary Order window. Keep bank records showing the date and amount of the transfer.
3. The investee company reports the qualifying investment in its annual tax return to the ITA, with the IIA certificate attached. The ITA registers the credit on the investor's file at this stage.
4. When you sell the shares and file the Israeli capital gains return, the accumulated credit applies against the capital gains tax owed. Foreign investors who do not otherwise file Israeli tax returns will need to file specifically for the exit year to claim the credit and recover any over-withheld amounts.

Foreign investors who have an Israeli Tax Identification Number (Mispar Mezahe Muzar, or "tax file number") should use it consistently across all ITA correspondence. Those without one should obtain one through the ITA Non-Residents Unit before the investment closes — the process typically takes two to three weeks and is done by mail or through an authorized Israeli tax representative.

7. The IIA IP transfer restriction: a critical risk for acquirers

Before investing in any company that has received IIA (Israel Innovation Authority) support — and many qualifying R&D companies have — foreign investors must understand a separate legal regime that sits alongside the Angels Law credit: the technology transfer restrictions under the Encouragement of Research, Development and Technological Innovation in Industry Law 5744-1984 (the R&D Law).

When an Israeli company has received IIA grants, the IIA retains legal rights over the intellectual property developed using those grants. Specifically, under Section 19B of the R&D Law, the company cannot transfer the IP or its know-how outside of Israel without IIA approval. This restriction attaches to the IP regardless of who owns the company's shares. A foreign acquirer who buys an IIA-grant-funded company and wants to move the IP offshore must obtain IIA approval — which typically requires paying a levy to the IIA of between one and three times the original grant amount.

This restriction affects exit planning directly. An American, European, or Asian acquirer buying an Israeli startup that received IIA grants cannot simply consolidate the IP into the parent company's IP holding jurisdiction without IIA approval and payment. Many foreign investors discover this only at the term sheet stage of an M&A process, when the IIA levy becomes a negotiating issue that can reshape deal economics significantly.

During due diligence, always request: (1) a complete list of all IIA grants received by the company; (2) the total grant amounts outstanding and unpaid royalties under those grants; (3) any IIA conditions or side letters attached to grant approvals; and (4) confirmation that the company's IP registry with the IIA reflects the current ownership structure.

8. Planning before the December 2026 deadline

The Temporary Order expires on December 31, 2026 — and the word "temporary" is not rhetorical. There have been prior Angels Law regimes that expired and were not renewed (the 2019 expiry went four years without reinstatement). Investors who want the credit must close their investments with cash transferred to the company's account on or before December 31, 2026.

Given the IIA certification process takes 30 to 60 days and due diligence on an early-stage Israeli company takes another 60 to 90 days, investors who want the credit in the 2026 tax year need to have identified their target companies and begun the process no later than September or October 2026.

Even if the Knesset extends the Temporary Order for a further period — which is possible but not certain — delaying investment in expectation of an extension is a bet on legislative action that has already failed once. The pragmatic approach is to treat December 31, 2026 as a real deadline.

For investors already in conversations with Israeli startups, the Angels Law credit adds a meaningful incentive to accelerate closing. A NIS 1 million investment generates NIS 250,000 in tax credit. On a larger NIS 4 million investment — the cap — the credit reaches NIS 1 million. That is a material return differential compared with the same investment made on January 1, 2027 with no credit available.